Dr. Brugarolas on rationale for targeting HIF2α in renal cell carcinoma

Video

“One of the processes that is regulated by HIF2α is angiogenesis,” says James Brugarolas, MD, PhD.

James Brugarolas, MD, PhD, director of the Kidney Cancer Program at Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, discusses the rationale for developing therapies for renal cell carcinoma that target HIF2α.

Related Videos
Nirmish Singla, MD, MSc, answers a question during a Zoom video interview
Human kidney cross section on scientific background | Image Credit: © Crystal light - stock.adobe.com
Nirmish Singla, MD, MSc, answers a question during a Zoom video interview
Carlos Muñoz-Lopez and Dr. Steven Campbell in an interview with Urology Times
Carlos Muñoz-Lopez and Dr. Steven Campbell in an interview with Urology Times
Dr. Michael Stifelman in an interview with Urology Times
Teona Iarajuli in an interview with Urology Times
hospital corridor
Related Content
© 2023 MJH Life Sciences

All rights reserved.